{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:06:30Z","timestamp":1767924390035,"version":"3.49.0"},"update-to":[{"DOI":"10.1016\/j.arres.2023.100064","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000}}],"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Redox Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.arres.2023.100064","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T18:15:24Z","timestamp":1674756924000},"page":"100064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["WITHDRAWN: Strong Dual Antipolymerase\/Antiexonuclease Actions of Some Aminothiadiazole Antioxidants: A Promising In-Silico\/In-Vitro Repurposing Research Study against the COVID-19 Omicron Virus (B.1.1.529.3 Lineage)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-114X","authenticated-orcid":false,"given":"Amgad M.","family":"Rabie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-201X","authenticated-orcid":false,"given":"Wafa A.","family":"Eltayb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arres.2023.100064_bib0001","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","article-title":"A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals","volume":"18","author":"Chitalia","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.arres.2023.100064_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.arres.2023.100064_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174233","article-title":"Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors \"leflunomide\" and \"teriflunomide\" in Covid-19: A narrative review","volume":"906","author":"Kaur","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arres.2023.100064_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100055","article-title":"Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19","volume":"2","author":"Rabie","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discovery"},{"key":"10.1016\/j.arres.2023.100064_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107831","article-title":"Cyanorona-20: The first potent anti-SARS-CoV-2 agent","volume":"98","author":"Rabie","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.arres.2023.100064_bib0006","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12879-021-05773-w","article-title":"Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study","volume":"21","author":"Ip","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.arres.2023.100064_bib0007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.arres.2023.100064_bib0008","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arres.2023.100064_bib0009","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/molecules26195795","article-title":"M.T. Alam, Abida, Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19","volume":"26","author":"Imran","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.arres.2023.100064_bib0010","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2174\/1389450121999201202110303","article-title":"Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance","volume":"22","author":"Moirangthem","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.arres.2023.100064_bib0011","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.arres.2023.100064_bib0012","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/pharmaceutics13091400","article-title":"Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro","volume":"13","author":"Brunotte","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.arres.2023.100064_bib0013","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1021\/acsomega.1c05998","article-title":"Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.arres.2023.100064_bib0014","doi-asserted-by":"crossref","first-page":"21385","DOI":"10.1021\/acsomega.1c07095","article-title":"Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.arres.2023.100064_bib0015","first-page":"1192","volume":"6","author":"Cai","year":"2020","journal-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering"},{"key":"10.1016\/j.arres.2023.100064_bib0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acsbiomedchemau.2c00039","article-title":"Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV\u20112 Repurposing Potential: In Silico and In Vitro Studies","volume":"2","author":"Rabie","year":"2022","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.arres.2023.100064_bib0017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1039\/D0NJ03708G","article-title":"Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs","volume":"45","author":"Rabie","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.arres.2023.100064_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109480","article-title":"Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles","volume":"343","author":"Rabie","year":"2021","journal-title":"Chem.-Biol. Interact."},{"key":"10.1016\/j.arres.2023.100064_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131106","article-title":"Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012\/01 strain","volume":"1246","author":"Rabie","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.arres.2023.100064_bib0020","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.arres.2023.100064_bib0021","unstructured":"https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants (last accessed October 26, 2022)."},{"key":"10.1016\/j.arres.2023.100064_bib0022","unstructured":"https:\/\/www.washingtonpost.com\/health\/2021\/12\/16\/omicron-variant-mutations-covid (last accessed April 4, 2022)."},{"key":"10.1016\/j.arres.2023.100064_bib0023","unstructured":"A.M. Rabie, A.S. Tantawy, S.M.I. Badr, Design, synthesis, and biological evaluation of new 5-substituted-1,3,4-thiadiazole-2-thiols as potent antioxidants, Researcher 10 (2018) 21\u201343. https:\/\/doi.org\/10.7537\/marsrsj100718.04."},{"key":"10.1016\/j.arres.2023.100064_bib0024","article-title":"Potent Dual Polymerase\/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico\/In Vitro Repositioning Research Study","volume":"65","author":"Rabie","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.arres.2023.100064_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.647693","article-title":"Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A High-Throughput in silico Screening","volume":"12","author":"Khater","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.arres.2023.100064_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105254","article-title":"5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis","volume":"198","author":"Zhao","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arres.2023.100064_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105078","article-title":"A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase","volume":"190","author":"Zhao","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arres.2023.100064_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113233","article-title":"Advance of structural modification of nucleosides scaffold","volume":"214","author":"Lin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.arres.2023.100064_bib0029","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.3390\/molecules26206151","article-title":"Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10","volume":"26","author":"Eissa","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.arres.2023.100064_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173634","article-title":"Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment","volume":"889","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arres.2023.100064_bib0031","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1080\/07391102.2021.1871956","article-title":"In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase","volume":"40","author":"Doharey","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.arres.2023.100064_bib0032","unstructured":"RdRp. Available from DrugDevCovid19, http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=RdRp&id=P0DTD1 (last accessed May 8, 2022)."},{"key":"10.1016\/j.arres.2023.100064_bib0033","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106379119","article-title":"Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN","volume":"119","author":"Moeller","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arres.2023.100064_bib0034","unstructured":"Nsp14. Available from DrugDevCovid19, http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=nsp14&id=P0DTD1 (last accessed May 8, 2022)."},{"key":"10.1016\/j.arres.2023.100064_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.arres.2023.100064_bib0036","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arres.2023.100064_bib0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.arres.2023.100064_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arres.2023.100064_bib0039","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/molecules27072180","article-title":"Thiazole\/Thiadiazole\/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2","volume":"27","author":"Petrou","year":"2022","journal-title":"Molecules"}],"updated-by":[{"DOI":"10.1016\/j.arres.2023.100064","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000}}],"container-title":["Advances in Redox Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667137923000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667137923000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:10:23Z","timestamp":1762978223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667137923000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"alternative-id":["S2667137923000036"],"URL":"https:\/\/doi.org\/10.1016\/j.arres.2023.100064","relation":{},"ISSN":["2667-1379"],"issn-type":[{"value":"2667-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Strong Dual Antipolymerase\/Antiexonuclease Actions of Some Aminothiadiazole Antioxidants: A Promising In-Silico\/In-Vitro Repurposing Research Study against the COVID-19 Omicron Virus (B.1.1.529.3 Lineage)","name":"articletitle","label":"Article Title"},{"value":"Advances in Redox Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arres.2023.100064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100064"}}